

## Jobkeeper Payments Notification

**Adelaide, Australia, 11 November 2021** – Nova Eye Medical Limited (ASX: EYE)(Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices provides the attached notice in accordance with subsection 323DB(1) of the Corporations Act 2021 (Cth).

***This release dated 11 November 2021 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.***

– ENDS –

### Company

Tom Spurling  
Managing Director  
Nova Eye Medical Limited  
W +61 417 818 658  
[tspurling@nova-eye.com](mailto:tspurling@nova-eye.com)

Kate Hunt  
Head of Marketing  
Nova Eye Medical Limited  
W +61 404 080 679  
[khunt@nova-eye.com](mailto:khunt@nova-eye.com)

### Investors

Dr. Tom Duthy  
Investor Relations & Corporate Development  
Nova Eye Medical Limited  
W +61 402 493 727  
[tduthy@nova-eye.com](mailto:tduthy@nova-eye.com)

## ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on

For personal use only

anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: [www.nova-eye.com](http://www.nova-eye.com)

# Jobkeeper Payments Notification

*A notice for release to the market under subsection 323DB(1) of the Corporations Act 2001-jobkeeper payments disclosure by listed entity.*

Date of this notice

05/11/2021

## Listed entity details

Australian Business Number (ABN)  
15007702927

ASX/NSX/SSX issuer code  
EYE

Name of the listed entity  
NOVA EYE MEDICAL LIMITED

## Jobkeeper payments

This notice relates to the financial years ended 30/06/2020 (FY 1) and 30/06/2021 (FY 2).

**The number of individuals for whom the listed entity or a subsidiary of the listed entity received a jobkeeper payment for a jobkeeper fortnight that ended in the financial year** *(within the meaning of the Coronavirus Economic Response Package (Payments and Benefits) Rules 2020).*

FY 1: 0

FY 2: 6

**The sum of all jobkeeper payments the listed entity, and each subsidiary of the listed entity, received in a jobkeeper fortnight that ended in the financial year.**

FY 1: \$0

FY 2: \$27,000

**Has the listed entity or a subsidiary of the listed entity, made one or more voluntary payments (whether or not in the financial year) to the Commonwealth by way of a repayment of jobkeeper payments received by the listed entity or a subsidiary of the listed in the financial year?**

NO

**If the listed entity or a subsidiary of the listed entity has made such a voluntary payment or payments -the sum of those payments:**

FY 1:\$0

FY 2:\$0